Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Novus Therapeutics Inc (NVUS) USD0.001

Sell:$0.72 Buy:$0.99 Change: $0.0048 (0.61%)
NASDAQ:1.35%
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Sell:$0.72
Buy:$0.99
Change: $0.0048 (0.61%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Sell:$0.72
Buy:$0.99
Change: $0.0048 (0.61%)
Market closed |  Prices as at close on 19 August 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.

Contact details

Address:
19900 Macarthur Blvd Ste 550
IRVINE
92612-8426
United States
Telephone:
+1 (949) 2388090
Website:
novustherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NVUS
ISIN:
US67011N1054
Market cap:
$10.12 million
Shares in issue:
12.97 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Keith Katkin
    Chairman of the Board, Independent Director
  • Catherine Turkel
    President
  • Gregory Flesher
    Chief Executive Officer, Director
  • Jon Kuwahara
    Senior Vice President - Finance and Administration

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.